Accordingly, the combination treatment of a ULK1 inhibitor with anti-PD1 increases tumor regression in a subcutaneous melanoma implant model through a reduction in PD-L1/L2 levels and enhances the infiltrating efficacy of anti-tumor immune cells [164]. This evidence concerns the gene CD274 and melanoma.